All Comments by Robert Vassar
Go to another page:
- 1
- 2
- Droplets in the Bucket? Introducing en Masse Single-Synapse RNA-Seq
- An isogenic panel of App knock-in mouse models: Profiling β-secretase inhibition and endosomal abnormalities.
- Single Synapse Mass Spec Snags CD47 as Alzheimer’s Resilience Factor
- Double Whammy: APP Uppsala Deletion Ups Aβ and Its Aggregation Propensity
- Aducanumab Approval Sparks Backlash
- Aducanumab Approved to Treat Alzheimer’s Disease
- What BACE Hits: New Substrates Create New Headaches
- Drop of Hope? No Cognitive Worsening on BACE Inhibitor
- Tau deletion reduces plaque-associated BACE1 accumulation and decelerates plaque formation in a mouse model of Alzheimer's disease.
- End of the BACE Inhibitors? Elenbecestat Trials Halted Amid Safety Concerns
- Bump in the Road or Disaster? BACE Inhibitors Worsen Cognition
- Enter Aη: Alternative APP Cleavage Creates Synaptotoxic Peptide
- Peer Pressure? "Pal" Leads APP Down Amyloid Path
- Identification of neuronal RNA targets of TDP-43-containing ribonucleoprotein complexes.
- Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus.